Today: 7 February 2026
Subscribe
Browse Category

Pfizer News 14 December 2025 - 30 December 2025

Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

NEW YORK, December 30, 2025, 13:50 ET — Regular session Pfizer Inc (NYSE:PFE) shares were up about 0.1% at $25.03 in afternoon trading on Tuesday, after moving between $24.92 and $25.10. TD Cowen reiterated its Hold rating and kept a $30 price target, pointing to negative trends in its model through 2030 despite the stock’s dividend yield near 7%. Investing.com The call lands as investors weigh Pfizer’s latest 2026 targets after the drugmaker projected revenue of $59.5 billion to $62.5 billion next year and adjusted earnings of $2.80 to $3.00 a share. “Adjusted” earnings strip out certain items the company
30 December 2025
·····
Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer Inc. (NYSE: PFE) stock is spending Christmas Eve in the familiar “mid-$20s” zone — a level that has become a psychological battleground for investors trying to decide whether Pfizer is a high-yield value play, a turnaround story, or simply a “show-me” stock until growth returns. As of Dec. 24, 2025, Pfizer shares were trading around $25 in holiday-thinned markets, leaving the company with a market capitalization of roughly $142 billion and keeping the conversation laser-focused on one question: Can Pfizer rebuild durable growth after the COVID-era revenue boom — and ahead of a looming patent cliff and intensifying U.S.
24 December 2025
·····
Pfizer (PFE) Stock After Hours: What’s Moving Shares After the Dec. 23, 2025 Close—and What to Watch Before Dec. 24’s Open

Pfizer (PFE) Stock After Hours: What’s Moving Shares After the Dec. 23, 2025 Close—and What to Watch Before Dec. 24’s Open

Pfizer (NYSE: PFE) ended Tuesday’s session (December 23, 2025) lower, then steadied in extended trading as investors digested a late-day safety headline tied to its hemophilia medicine Hympavzi (marstacimab). After-hours snapshot (as of 6:56 p.m. ET): PFE traded around $24.92, up about 0.16% in after-hours action, after closing the regular session at $24.88. Yahoo FinanceDuring Tuesday’s regular session, PFE ranged roughly between $24.84 and $25.34 with volume near 43.7 million shares. Where Pfizer Stock Closed on Dec. 23—and Why the Tape Looked “Holiday Thin” PFE closed down 1.31% at $24.88, snapping a two-day winning streak even as the broader market
24 December 2025
·····
Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Dec. 23, 2025 — Pfizer Inc. (NYSE: PFE) stock is ending 2025 in a familiar tug-of-war: a high-yield “value” profile on the one hand, and lingering uncertainty about the company’s post‑COVID growth engine on the other. Shares were trading around $25.15 on Tuesday, keeping the stock in the mid‑$20s range that’s defined much of its recent tape. Today’s news flow adds another variable for investors to price: a safety-related update tied to Pfizer’s hemophilia therapy Hympavzi, landing just as Wall Street digests Pfizer’s newly issued 2026 outlook and the company’s longer road back to growth. What’s moving Pfizer stock on
23 December 2025
·····
Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

As of Monday, December 22, 2025, Pfizer (NYSE: PFE) is once again at the center of a familiar market debate: is this a battered pharma giant destined to stay “dead money,” or a dividend-rich turnaround story that could surprise investors as its pipeline matures? The short-term reality is tough to miss. Pfizer has guided to flat-to-down revenue in 2026, with continued COVID-franchise erosion and an accelerating loss-of-exclusivity cycle. But the longer-term case—outlined in a wave of investor and analyst commentary this month—rests on whether Pfizer can execute in the two areas that matter most to its post-patent-cliff future: oncology and
22 December 2025
·····
Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer’s stock is ending 2025 in a familiar place: caught between near-term headwinds (shrinking COVID-era revenue, a growing patent cliff, and U.S. drug-pricing pressure) and a late-decade recovery narrative built around oncology, obesity, and pipeline execution. As of the latest available trade/close data around Dec. 20, Pfizer shares are near $25.19, modestly higher on the most recent session. Investing.com That price level matters because it frames the debate investors are having right now: Is PFE a high-yield “wait-it-out” turnaround, or a value trap until new launches and major clinical wins begin to offset upcoming losses of exclusivity? Below is a
21 December 2025
·····
Pfizer Stock After Hours Today (Dec. 18, 2025): PFE Holds Near $25 — What to Know Before Friday’s Market Open

Pfizer Stock After Hours Today (Dec. 18, 2025): PFE Holds Near $25 — What to Know Before Friday’s Market Open

Pfizer Inc. (NYSE: PFE) ended Thursday’s session essentially flat and stayed steady in after-hours trading, a sign that investors are still digesting the company’s newly issued 2026 outlook while watching a fast-evolving U.S. policy backdrop around drug pricing. As of early evening in New York, Pfizer shares were hovering around $25.05 in after-hours trading, after finishing the regular session at $25.04. Google Below is what moved the conversation around Pfizer today, what the latest forecasts imply, and the key items to monitor before the stock market opens Friday (Dec. 19, 2025). Pfizer stock after the bell: where PFE stands heading
19 December 2025
·····
Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer Inc. (NYSE: PFE) shares fell sharply in U.S. trading on Tuesday, December 16, 2025, as investors weighed the drugmaker’s first look at full-year 2026 guidance, an updated 2025 revenue outlook, and fresh commentary on cost savings and capital allocation. By late morning ET, Pfizer stock was trading around $25, down roughly 5% on the day after swinging between the mid-$26s and just under $25. The market’s message was clear: Pfizer’s transition away from pandemic-era revenue is still a work in progress, and 2026 is shaping up as another “bridge year” where lower COVID-19 sales and patent expirations pressure results—partly
16 December 2025
·····
Pfizer Stock After Hours (PFE) on Dec. 15, 2025: What Moved Shares Today—and What to Watch Before Tuesday’s Open

Pfizer Stock After Hours (PFE) on Dec. 15, 2025: What Moved Shares Today—and What to Watch Before Tuesday’s Open

Pfizer Inc. (NYSE: PFE) ended Monday’s session on a strong note, then traded slightly lower after the closing bell as investors shifted their attention to the next major catalyst: Pfizer’s scheduled analyst call Tuesday morning, where management is expected to outline full-year 2026 financial guidance. Yahoo Finance+2Pfizer+2 In regular trading, Pfizer shares closed at $26.43, up 2.24% on the day. After hours, the stock was modestly lower, trading around $26.34 (down 0.34%) as of early evening. Yahoo Finance Below is what mattered most for Pfizer stock after the bell on Monday, December 15, 2025, and what investors typically want on
16 December 2025
····
Pfizer Stock (PFE) News, Forecasts, and Analyst Outlook: What’s Driving Shares on December 15, 2025

Pfizer Stock (PFE) News, Forecasts, and Analyst Outlook: What’s Driving Shares on December 15, 2025

Pfizer, Inc. (NYSE: PFE) is back in focus on Monday, December 15, 2025, with investors weighing fresh collaboration news, a looming guidance event, and a familiar debate: is Pfizer stock a high-yield value play with a rebuilding pipeline—or a “wait-and-see” story facing years of patent headwinds? As of Monday’s session, Pfizer stock is trading around $26.36. That places PFE near the upper end of its recent trading band and within reach of its 52-week high of $27.69 (52-week low $20.92), underscoring how tightly the stock has ranged as markets await clearer 2026 direction. MarketBeat+1 Below is a detailed, news-driven look
15 December 2025
·····
Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer Inc. (NYSE: PFE) enters the new week with its stock hovering around $25.85 in early Monday trading, as investors weigh a familiar late-2025 mix: a high dividend, a rebuilding growth story after the COVID boom, and a pipeline/M&A strategy designed to refill the revenue engine ahead of major patent cliffs. The immediate spotlight is tomorrow morning’s full-year 2026 guidance call—a scheduled catalyst that can reset expectations for revenue, margins, and capital allocation going into 2026. Pfizer Pfizer stock price today: where PFE stands on Dec. 15, 2025 As of 12:08 UTC on Monday, Pfizer shares traded at $25.85, essentially
15 December 2025
·····
Pfizer Stock (PFE) Outlook: This Week’s Key Headlines, Dividend Update, and What to Watch Ahead of 2026 Guidance (Updated Dec. 14, 2025)

Pfizer Stock (PFE) Outlook: This Week’s Key Headlines, Dividend Update, and What to Watch Ahead of 2026 Guidance (Updated Dec. 14, 2025)

Pfizer Inc. (NYSE: PFE) heads into the new trading week with investors balancing two very different storylines: a steady, high-yield “value pharma” profile versus a news-driven catalyst tape around obesity deals, oncology data, cost cuts, and shifting U.S. COVID-vaccine policy. As of the latest close, Pfizer shares were around $25.85. With markets closed on Sunday (Dec. 14), the next big directional test arrives quickly: Pfizer’s analyst and investor call on Tuesday, Dec. 16, where management is scheduled to provide full-year 2026 financial guidance. Pfizer+1 Below is a detailed, news-driven look at what moved Pfizer stock in recent days—and what could
14 December 2025
·····
1 2 3

Stock Market Today

iFAST share price drops 3% as markets shut; earnings next week in focus

iFAST share price drops 3% as markets shut; earnings next week in focus

7 February 2026
iFAST shares fell 3.2% to S$9.64 in heavy trading Friday, closing near the day’s low as investors awaited FY2025 results due Feb. 12. The stock is about 13% below its 52-week high. iFAST recently agreed to buy a 30% stake in Financial Alliance for S$19.6 million, pending regulatory approval. Assets under administration stood at S$30.62 billion as of Sept. 30.
Sembcorp Industries share price: what to watch after Friday dip as Feb 25 results near

Sembcorp Industries share price: what to watch after Friday dip as Feb 25 results near

7 February 2026
Sembcorp shares closed at S$6.05 on Friday, down 0.33%, as Singapore’s STI dropped 0.8%. Shareholders approved the A$6.5 billion Alinta Energy takeover on Jan 30, but the deal still faces regulatory and closing conditions. Sembcorp will release FY2025 results on Feb 25 before market open. Trading volume reached about 4.3 million shares.
Hongkong Land share price drops 4% despite fresh buyback — what investors watch next

Hongkong Land share price drops 4% despite fresh buyback — what investors watch next

7 February 2026
Hongkong Land shares fell 4.2% to US$8.18 in Singapore on Friday after the company disclosed a buyback of 170,000 shares at US$8.5252 each on Feb. 5, with plans to cancel them. The drop followed a volatile week marked by a new Singapore real estate fund launch and an expanded buyback programme. Investors are watching for the group’s annual results on March 5.
Go toTop